Cycloguanil and Analogues Potently Target DHFR in Cancer Cells to Elicit Anti-Cancer Activity

Dihydrofolate reductase (DHFR) is an established anti-cancer drug target whose inhibition disrupts folate metabolism and STAT3-dependent gene expression. Cycloguanil was proposed as a DHFR inhibitor in the 1950s and is the active metabolite of clinically approved <i>plasmodium</i> DHFR inhibitor Pro...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Jennifer I. Brown, Peng Wang, Alan Y. L. Wong, Boryana Petrova, Rosanne Persaud, Sepideh Soukhtehzari, Melanie Lopez McDonald, Danielle Hanke, Josephine Christensen, Petar Iliev, Weiyuan Wang, Daniel K. Everton, Karla C. Williams, David A. Frank, Naama Kanarek, Brent D. G. Page
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	MDPI AG 2023-01-01
Цуврал:	Metabolites
Нөхцлүүд:	dihydrofolate reductase folate metabolism target engagement cancer therapy cycloguanil breast cancer
Онлайн хандалт:	https://www.mdpi.com/2218-1989/13/2/151
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!